Abstract 468P
Background
Traditional Chinese Medicine (TCM) is effective in alleviating side-effects of radiotherapy and chemotherapy. While TCM is popular among cancer patients, their health-seeking behavior is not well described. Safety data regarding concurrent use with oncology treatment is lacking.
Methods
This is a retrospective cohort study from a tertiary oncology institute. All patients who had follow-up visits in both the TCM clinic and Oncology department of the Queen Elizabeth Hospital in Hong Kong from 2011 to 2022 were recruited.
Results
Fourteen patients were identified. Twelve (85.7%) were female, median age was 64. Nine (64.3%) of them were early-stage (I-II) cancers. Amongst these 14 patients, the distribution of cancer types was as follows: breast cancer (n=6), cervical cancer (n=3), head and neck cancer (n=2), ovarian cancer (n=2) and gastrointestinal cancer (n=1). Eight (57.4%) patients started to receive TCM advice at the same year of diagnosis, while half of them received conventional cancer treatment (chemotherapy, n=2; targeted therapy, n=1; hormone therapy, n=1) simultaneously. No CTCAE v5 Grade 3 or above adverse events were observed among patients having the concomitant use of TCM and chemotherapy. However, none of them informed the oncologist regarding the use of TCM. Patients tends to complain more symptoms to TCM practitioner than to Oncologists. The major reasons for TCM treatments were the treatment-emergent side effects (n=9), followed by the wish for reconditioning after anti-cancer treatment (n=6). Patients reported that the use of herbal medicine (H) improved insomnia (3 out of 4 pts), dizziness (n=1) and cancer pain (n=1). Moreover, the combined use of H and acupuncture showed clinical improvement in chemotherapy-induced numbness (1 out of 2 pts), pain associated with avascular necrosis (n=1), fatigue (n=1) and alopecia (n=1).
Conclusions
TCM demonstrated promising results in improving long-term treatment morbidity. Yet, most patients were not willing to disclose the use of TCM. Strengthening the communication between oncologists and patients would reduce the potential risk of herb-drug interactions.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract